№ files_lp_4_process_2_78836
File format: docx Character count: 127056 File size: 361 KB
This document is a clinical submission for the inclusion of patiromer in the Australian Pharmaceutical Benefits Scheme (PBS) for the treatment of chronic hyperkalaemia in CKD patients on RAASi therapy.
Year: 2020
Region / city: Australia
Theme: Health, pharmaceutical, clinical treatment
Document type: Submission for drug listing
Organization / institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: Vifor Pharma Pty Limited
Target audience: Healthcare professionals, regulatory bodies
Period of validity: Ongoing
Approval date: 12 December 2017
Amendment date: November 2020
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Appeal for Coverage of VELTASSA® (patiromer) for Oral Suspension
Year: 2023
Region / City: Not specified
Topic: Medical Treatment Appeal
Document Type: Appeal Letter
Institution / Organization: Not specified
Author: [Prescriber’s Name]
Target Audience: Medical director, insurance company
Period of Validity: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Update _2_0_411 Clinical Reminders VA-NEPHROLOGY CKD CONSULT RESULT Install GuideMarch 2024
Year: 2024
Region / City: United States
Subject: Clinical Reminders, Nephrology, Chronic Kidney Disease, Medical Template
Document Type: Installation Guide
Organization: Department of Veterans Affairs
Author: Office of Information Technology
Target Audience: VA Nephrology/Kidney Medicine Physicians
Period of validity: Not specified
Approval Date: Not specified
Modification Date: Not specified
Anaemia in Chronic Kidney Disease (CKD)
Year: 2017
Region / City: N/A
Topic: Nephrology, Anaemia, Chronic Kidney Disease
Document Type: Patient Information
Organization / Institution: Nephrology Department
Author: Emma Head
Target Audience: Patients with Chronic Kidney Disease
Effective Period: N/A
Approval Date: N/A
Modification Date: N/A
Business Rules for Quality and Outcomes Framework (QOF) 2023/2024-2024/2025 Chronic kidney disease (CKD)
Year: 2023/2024
Region / city: NHS England
Topic: Healthcare, Quality and Outcomes Framework (QOF)
Document type: Business rules, Technical specification
Organization / institution: NHS England
Author: General Practice Specification and Extraction Service (GPSES), NHS England
Target audience: General practitioners, GP system suppliers
Period of validity: 2023–2024
Approval date: 01/04/2023
Amendment date: 01/04/2024
Description: This document provides the technical business rules and dataset specifications for Chronic Kidney Disease (CKD) under the Quality and Outcomes Framework (QOF) for use by NHS England and General Practice Systems.
Topics: RAASi patiromer CKD